The long-term outcome of non-A, non-B post-transfusion hepatitis was evaluated in 21 patients who developed the illness after open-heart surgery and could be followed thereafter up to five years. Histological chronic sequelae were documented in 13 patients, and consisted of chronic persistent hepatitis in one case, chronic lobular hepatitis in two and chronic active hepatitis in 10, five of whom also developed superimposed cirrhosis. Progression to these chronic states was in most cases symptomless, independently of the severity of liver lesions; one patient, however, died of gastrointestinal bleeding due to cirrhosis of the liver. During follow-up the biochemical pattern of chronic non-A, non-B hepatitis was unique, with striking fluctuations of transaminase levels. Liver histology proved essential to identify the severity of chronic liver lesions, as clinical and biochemical features were uniform and not indicative of it. Our results suggest that cirrhosis may develop, often with an asymptomatic course, in a significant number of patients who do not recover after acute post-transfusion non-A, non-B hepatitis.
In spite of routine screening of blood donors for hepatitis B surface antigen (HBsAg), blood recipients remain at significant risk of developing posttransfusion hepatitis that in up to 90% of the cases is unrelated to type A or B virus infection; it is therefore termed non-A, non-B hepatitis. ' Volunteers and animal studies have provided evidence that non-A, non-B hepatitis is caused by transmissible agents,2 4 but the possibility of identifying the infection by specific serological markersS 6 is still under investigation.
Nevertheless, some relevant clinical features of the disease have already been described in patients with post-transfusion hepatitis in whom non-A, non-B infection could be diagnosed by exclusion criteria.
Prospective studies of post-transfusion hepatitis7 8 have shown that, although most of the patients with non-A, non-B hepatitis remain anicteric and asymptomatic, up to 50% of them may be found to have abnormal transaminase levels for longer than one year after onset, with histological evidence of signi-*Addrcss for corrcspondencc: Dr Giuseppe Realdi. Istituto di Medicina Clinica. Via Giustiniani 2, Policlinico dcllUniversitia. Received for publication 1) September 1981 ficant liver disease. Berman et al. 9 have recently reported that these chronic sequelae often show a tendency towards spontaneous biochemical remission suggesting that chronic non-A, non-B hepatitis could be a slowly resolving rather than a chronically progressing disease. One patient in their study, however, did develop cirrhosis, and this is also documented by other authors.7 ""'
We report here the long-term outcome of non-A, non-B post-transfusion hepatitis in 21 patients who developed a symptomatic disease after open-heart surgery and were followed for up to five years after onset. In seven of these patients serial liver biopsies were available during the acute phase and afterwards, giving evidence of the progression of acute disease to various histologically demonstrable chronic processes including cirrhosis of the liver.
Methods

PATIENTS
Twenty-one patients who developed non-A. non-B post-transfusion hepatitis after open-heart surgery were considered for this study. None of them showed biochemical evidence of liver disfunction before 270
Long-termfollow-up ofnon-A, non-B hepatitis operation, but transaminase levels became abnormal (over three times the upper limit of the normal range) two to 12 weeks after they had received eight to 23 units of whole blood or plasma during surgery. Exposure to liver toxins, such as alcohol or drugs, and congestive heart failure could be excluded in all 21 patients whom radioimmunoassay (RIA, Abbott) showed to be HBsAg negative at repeated testing during the acute phase of the illness.
Of the 21 patients, 15 (group A) were seen in our unit during acute hepatitis, when IgM antibody to hepatitis A virus (anti-HAV) was proven negative by radioimmunoassay (Abbott) in all cases; antibody to HBsAg (anti-HBs) and antibody to hepatitis B core antigen (anti-HBc) were also negative by radioimmunoassay (Abbott) in 13 cases, while two were already anti-HBs and anti-HBc positive when they were administered. All these 15 patients underwent liver biopsy during the acute phase and were then followed up at three to six monthly intervals in our outpatient clinic. Those cases in whom transaminase levels remained raised for more than 12 months after onset underwent subsequent liver biopsies to assess the development of chronic liver disease.
The remaining six patients (group B) had been referred to our unit because abnormal transaminase levels persisted eight to 22 months after acute non-A, non-B post-transfusion hepatitis. All Fig. 1 , seven of these eight patients underwent subsequent liver biopsy that led to a diagnosis of chronic lobular hepatitis in two cases and of chronic active hepatitis in five, two of whom also showed associated cirrhotic changes.
There was no significant difference between the seven patients who recovered and those who progressed to chronic hepatitis, when several clinical and biochemical features in the acute phase were compared ( Table 2 ). As shown in Fig. 2 , the difference in alanine aminotransferase values between these two groups of patients became statistically significant after the sixth month of follow-up. Where histology 
LONG-TERM FOLLOW-UP OF CHRONIC NON-A, NON-B HEPATITIS
The 14 patients in whom non-A, non-B posttransfusion hepatitis progressed to a chronic stage (eight cases in group A and six cases in group B) were followed up to 23-58 months after acute onset. Four patients complained only of mild symptoms suggestive of chronic liver disease. Nine patients, including all but one of those with cirrhosis, remained symptomless during the follow-up. Development of ascites or of encephalopathy was not observed in any of the patients. One patient (case no. 9, Fig. 1 ) died of gastrointestinal bleeding 18 months after the diagnosis of chronic active hepatitis with cirrhosis had been made.
The biochemical behaviour of the disease in the 14 During the follow-up, nine of the 10 patients with chronic active hepatitis were started on immunosuppressive therapy with 16 mg/day prednisolone alone (five cases) or combined with 50 mg/day azathioprine (four cases). The five cases who did not receive immunosuppressive drugs (two chronic lobular hepatitis, one chronic persistent hepatitis, one chronic active hepatitis, and one patient in whom liver biopsy was not available) continued to show the same pattern of transaminases and in none of them was sustained normalisation of enzymes observed. In contrast, among the nine patients started on therapy, eight showed a progressive reduction of transaminases and in seven of them enzyme levels persistently either returned to normality or, although raised, remained lower than twice the upper limit of normality. In six of these patients on immunosuppressive treatment a new liver biopsy was taken 10 to 21 months later (Fig. 1, Table 3 ). In two of them (one chronic active hepatitis, one chronic active hepatitis with cirrhosis) the histological diagnosis remained unchanged, while in three other patients with chronic active hepatitis and cirrhosis there was almost complete disappearance of inflammatory activity; in another patient with chronic active hepatitis regression to chronic persistent hepatitis was noted, although his alanine aminotransferase values remained abnormal.
As regards development of cirrhosis in our patients with non-A, non-B hepatitis, it was noted that cirrhotic changes had already become evident in only one out of eight patients who were biopsied one to two years after onset, compared with four out of six untreated patients biopsied at later stages (between the second and the fourth year of illness). Thus, in our series of patients with non-A, non-B post-transfusion hepatitis, the long-term evolution was more severe than that suggested by previous studies,89 and included development of cirrhosis in a significant number of patients, one of whom eventually died of gastrointestinal bleeding.
Possible explanations for these discrepancies could relate to the duration of our follow-up or to the type of patients considered. Indeed, in most of our cases cirrhotic changes were noted in biopsies taken more than two years after onset, while biopsies taken at earlier stages were usually free of cirrhosis. In addition, nearly all of our patients had symptomatic acute disease, although symptoms disappeared after the acute phase in many patients who progressed to chronic hepatitis. In contrast, in published series of patients with non-A, non-B post-transfusion hepatitis, asymptomatic cases largely predominated.
These differences could indicate that symptomatic acute non-A, non-B hepatitis, unlike hepatitis B virus infection, may pursue a more severe chronic course compared with asymptomatic acute disease.
In our patients, the clinical features of the acute phase, and also most of the biochemical findings, were not indicative of the course of the illness. The presence of piecemeal necrosis in acute phase liver biopsies was highly indicative of chronic evolution, although not of its histological severity. Development of chronic liver lesions, however, including cirrhosis also occurred in three patients who had typical acute histological features in the first liver biopsy.
Serial determination of transaminase levels for a prolonged period of time represented in our patients the most reliable way of identifying chronic sequelae. As also underlined by other authors,' 9 the pattern of behaviour of liver enzymes was, in these patients, unique, with striking fluctuations in time including phases of normality. Sustained normality of transaminases occurred more than one year after onset in few patients who then seemed to be cured, but all those who continued to show abnormal values for more than 18 months progressed to chronic lesions. In these patients liver histology was essential in order to identify the severity of the hepatic involvement, as the clinical and biochemical pattern was not indicative of the degree of liver damage.
No conclusions can be reached on the effect of immunosuppressive therapy in our patients with chronic non-A, non-B hepatitis. Most patients on therapy showed improvement of transaminase levels and in some of them reduction in inflammatory activity was also noted in the liver. Clearly, however, only a controlled trial can decide whether immunosuppressive drugs are needed in chronic non-A, non-B liver disease. 
